Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Rare disease

Hereditary angioedema with C1 esterase inhibitor deficiency

  • 10 clinical trials
Quick filters

10 Clinical trials

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Recruiting

A study of navenibart for long-term safety in patients with hereditary angioedema

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Navenibart
  • Sponsor:Astria Therapeutics Inc.

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Recruiting

Study on C1 Esterase Inhibitor for Treating and Preventing Hereditary Angioedema Attacks in Patients with C1-INH Deficiency

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Octapharma Pharmazeutika Produktionsgesellschaft mbH

Hereditary angioedema with C1 esterase inhibitor deficiency

Recruiting

Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Not recruiting

Study of navenibart to prevent attacks in adults and adolescents with Hereditary Angioedema

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Navenibart
  • Sponsor:Astria Therapeutics Inc.

Hereditary angioedema with C1 esterase inhibitor deficiency

Not recruiting

Study on the Safety and Effects of Sebetralstat for Children Aged 2-11 with Hereditary Angioedema Type I or II

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Sebetralstat
  • Sponsor:Kalvista Pharmaceuticals Limited

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Not recruiting

Study on the Long-Term Safety of STAR-0215 for Adults with Hereditary Angioedema

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Navenibart
  • Sponsor:Astria Therapeutics Inc.
See all trials →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.